China International Search and Rescue Team

INmune Bio Inc. Announces Third Quarter 2023 Results and Provides Business Update

Retrieved on: 
Wednesday, November 1, 2023
Research, AD, Food, Health care, Biomarker, ATCC, Macrophage, World Intellectual Property Organization, Data, White matter, Phase, MHRA, MRI, MDS, CELL, Hereditary leiomyomatosis and renal cell cancer syndrome, Prostate cancer, Dementia, China International Search and Rescue Team, ATCC (company), Phagocytosis, EEG, Cancer, Patient, MS, BOCA, Human, Neurodegenerative disease, Conference, CTA, Patent Cooperation Treaty, AAIC, PCT, NK, Brain, Remyelination, Grey, AML, Carcinoma, FDA, IND, Medication, CNS, Treatment-resistant depression, Drug development, Pharmacotherapy, Neuroinflammation, WIPO, Cross, Cognition, Vaccine, Pharmaceutical industry, Medical imaging, Cryptocurrency, Health, Immunotherapy, Disease

BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.

Key Points: 
  • BOCA RATON, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2023 and provides a business update.
  • Recruitment of the trial is increasing and the company anticipates results of the Phase II program towards the end of 2024.
  • Other expense was approximately $0.0 million for the quarter ended September 30, 2023, compared to approximately $0.3 million during the quarter ended September 30, 2022.
  • Please ask for the INmune Bio Third Quarter Conference Call when reaching an operator.

INmune Bio Inc. Patent Claims Covering INB16 Cell Line and INKmune™ Therapeutic Composition given Favorable Patentability Opinion by International Search Authority

Retrieved on: 
Tuesday, October 31, 2023
Patient, IND, PSA, Patent, Leukemia, Progression-free survival, Biomarker, Art, Ligand, World Intellectual Property Organization, CD15, Invention, CELL, Hematological Cancer Research Investment and Education Act, Patent Cooperation Treaty, Cell, EPO, Administration, China International Search and Rescue Team, Disease, ATCC (company), NK, Cancer, WIPO, CT, Blood, TME, General counsel, CD2, Immunosuppression, Hypoxia, Insurance, Vaccine, Pharmaceutical industry

Boca Raton, Florida, Oct. 31, 2023 (GLOBE NEWSWIRE) --  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, announced an update regarding the company’s patent covering its proprietary cell line, “INB16”, as well as the therapeutic composition comprising replication-incompetent INB16 cells known as “INKmune™” and methods of treating cancer by administering INKmune™, with a goal of achieving in vivo priming of natural killer (NK) cells to enhance the ability of a patient’s own NK-cells to effect cancer surveillance, recognition, and killing.

Key Points: 
  • INmune Bio receives International Search Report and Written Opinion communicating possession of novelty, inventive step, and industrial applicability in all claims pending in an international patent application covering, among other things, its proprietary cell line, INB16, and the INKmune™ therapeutic composition.
  • The application discloses and claims the novel INB16 cell line on deposit with the American Type Culture Collection, as well as compositions comprising replication incompetent INB16 cells (“INKmune™”) and methods of treating cancer in patients by administering INKmune™.
  • “Patents covering novel cell lines are somewhat rare in practice and form a very small number of total patents issued,” said Joshua Schoonover, Esq., in-house General Counsel for the Company.
  • INB16 is a tumor cell line which is relatively insensitive to killing by natural killer (NK) cells from healthy donors and from patients.

The Patent Cooperation Treaty (PCT) Provides Positive Opinion on BYND Cannasoft’s AI-Based Female Treatment Device

Retrieved on: 
Tuesday, April 25, 2023
Pressure, Communication, CSE, Female, Feedback, China International Search and Rescue Team, ISR, Examination, BYND, Temperature, Patent Cooperation Treaty, PCT, USD, BCAN, US, Patent, Machine learning, Algorithm, Pain management, Artificial intelligence, AI, Fluid mechanics, Heart rate, Medical device, Pharmaceutical industry

ASHKELON, Israel and VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") announced today it has received a positive opinion from the Patent Cooperation Treaty (PCT) for its Artificial Intelligence (AI) Sex Tech-based Female Treatment Device.

Key Points: 
  • ASHKELON, Israel and VANCOUVER, British Columbia, April 25, 2023 (GLOBE NEWSWIRE) -- BYND Cannasoft Enterprises Inc. (Nasdaq: BCAN) (CSE: BYND) ("BYND Cannasoft" or the "Company") announced today it has received a positive opinion from the Patent Cooperation Treaty (PCT) for its Artificial Intelligence (AI) Sex Tech-based Female Treatment Device.
  • By collecting data from its sensors, the device will adjust stimulation patterns and determine the lubricant dispensing rate, thereby facilitating sexual climax.
  • Should BYND Cannasoft receive a patent from the PCT, it can benefit in several ways:
    Global Protection: A PCT patent application protects in all PCT member countries.
  • Time to Decide: The PCT process provides a company additional time to decide in which countries to pursue patent protection.

Iterum Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results

Retrieved on: 
Thursday, March 16, 2023
Therapy, Clinical trial, Prejudice, Regulation of tobacco by the U.S. Food and Drug Administration, R, Probenecid, SPA, Patent, Urinary tract infection, Senior, District court, ITRM, Investment, Woman, Research, FDA, China International Search and Rescue Team, National Renewable Energy Laboratory, G&A, Consultant, Infection, IV, Food, NDA, United States Patent and Trademark Office, Pharmaceutical industry, Cryptocurrency, Sulopenem

DUBLIN, Ireland and CHICAGO, March 16, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the fourth quarter and year ended December 31, 2022.

Key Points: 
  • Patents Issued: The United States Patent and Trademark Office has issued Iterum two new patents: 1) US Patent No.
  • In addition, during the fourth quarter of 2022, a change in the discount rate impacted the fair value of the Limited Recourse Royalty-Linked Subordinated Notes (the “Royalty-Linked Notes”).
  • Non-GAAP1 net loss for the fourth quarter and full year 2022 of $6.4 million and $22.9 million, respectively, compared to a non-GAAP1 net loss of $3.3 million and $19.4 million for the same periods in 2021.
  • Iterum will host a conference call today, Thursday, March 16, 2023 at 8:30 a.m. Eastern Time.

Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem

Retrieved on: 
Thursday, December 15, 2022
Hand, IV, China International Search and Rescue Team, Clinical trial, Probenecid, Penem, Security (finance), Bacteria, Food, FDA, Public policy, Patent, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, QIDP, Legislation, Urinary tract infection, ITRM, Infection, Therapy, COVID-19, Pharmaceutical industry

If approved, oral sulopenem will be the first oral penem available in the United States,” said Corey Fishman, Chief Executive Officer.

Key Points: 
  • If approved, oral sulopenem will be the first oral penem available in the United States,” said Corey Fishman, Chief Executive Officer.
  • The recently issued U.S. patent for oral sulopenem entitled “Combinations of Beta-Lactam Compounds and Probenecid and Uses Thereof” also expires in 2039, absent any extensions.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

Iterum Therapeutics Reports Third Quarter 2022 Financial Results

Retrieved on: 
Thursday, November 10, 2022
Adult, Probenecid, Therapy, Senior, SPA, Security (finance), Compliance, Urinary tract infection, CRL, IV, Forward-looking statement, Exchangeable, United States Patent and Trademark Office, Patent, Food, Hand, BID, SEC, Compte rendu, Public policy, Penem, U.S. Securities and Exchange Commission, Research, GAAP, Patient, Note, COVID-19, Phrase, Nasdaq, FDA Special Protocol Assessment, Legislation, Regulation of tobacco by the U.S. Food and Drug Administration, ITRM, Finance Secretary (India), Clinical trial, Renewable Energy Derivative, Bacteria, Woman, Infection, Table, NDA, FDA, Income, GLOBE, Intellectual property, Investment, Maturity, China International Search and Rescue Team, Pharmaceutical industry, Bank

DUBLIN, Ireland and CHICAGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (“Iterum”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2022.

Key Points: 
  • DUBLIN, Ireland and CHICAGO, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported financial results for the third quarter ended September 30, 2022.
  • U.S. Patent Issued Extending Protection: The United States Patent and Trademark Office (USPTO) has issued Iterum a new patent, No.
  • Research and development (R&D) expenses for the third quarter of 2022 were $4.4 million compared to $1.8 million for the same period in 2021.
  • General and administrative (G&A) expenses for the third quarter of 2022 were $2.7 million compared to $3.0 million for the same period in 2021.

InspiraTM Technologies Granted Patent by the Israeli Patent Office for Key Safety Component for the INSPIRATM ART System

Retrieved on: 
Thursday, November 10, 2022
Patient safety, Program, Hospital, Coma, Risk, OXY, Patent, Form 20-F, Annual report, Technology, Bleeding, Extracorporeal membrane oxygenation, Proton Inspira, ECMO, SEC, ISA, NASDAQ, Solution, Unitary state, U.S. Securities and Exchange Commission, Safety, Company, World Intellectual Property Organization, China International Search and Rescue Team, Human, Transport, Intubation, WIPO, National Association Medical Staff Services, Patient, CEO, Neck, ART, Pharmaceutical industry, Medical device

Ltd. (NASDAQ: IINN) (NASDAQ: IINNW)(the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that the Israeli Patent Office (ILPO) granted a patent for a key safety component of the INSPIRATM ART system.

Key Points: 
  • Ltd. (NASDAQ: IINN) (NASDAQ: IINNW)(the "Company" or "Inspira Technologies"), a groundbreaking respiratory support technology company, announced today that the Israeli Patent Office (ILPO) granted a patent for a key safety component of the INSPIRATM ART system.
  • The component is to be located on the patient's neck and is designed to secure a neck cannula from moving or dislodging.
  • The Company has developed a breakthrough Augmented Respiration Technology (INSPIRA ART), designed to rebalance patient oxygen saturation levels.
  • The Company's products have not yet been tested or used in humans and has not been approved by any regulatory entity.

Iterum Therapeutics announces Issuance of Allowance for a U.S. Patent Covering Oral Sulopenem

Retrieved on: 
Monday, September 19, 2022
Penem, Infection, IV, COVID-19, China International Search and Rescue Team, FDA, Food, ITRM, Legislation, Company, Public policy, Therapy, U.S. Securities and Exchange Commission, Hand, Forward-looking statement, Clinical trial, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Phrase, Probenecid, United States Patent and Trademark Office, QIDP, Bacteria, Nasdaq, Patent, Urinary tract infection, Security (finance), GLOBE, SEC, Pharmaceutical industry

This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed.

Key Points: 
  • This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed.
  • Existing patent protection for sulopenem etzadroxil is scheduled to expire in 2029, subject to potential extension.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.

New CGI Sense360 data analytics platform improves situational awareness for disaster rescue teams

Retrieved on: 
Wednesday, July 27, 2022
Data management, TSX, European Space Agency, GIB, Airport, First Nations in Ontario, Lists of disasters, Consultant, United Nations, CGI, Social media, NYSE, ESA, Police, Tsunami, Solution, Australian Space Agency, Artificial intelligence, Accident, Weather, Organization, Flood, Senior, Ecosystem, System, International, Earthquake, China International Search and Rescue Team, Emergency, Satellite navigation device, Risk management

HAMBURG, BOCHUM and DARMSTADT, Germany, July 27, 2022 /PRNewswire/ - CGI (NYSE: GIB) (TSX: GIB.A) announces CGI Sense360, its cloud-based, smart analytics platform that gives emergency responders holistic and accurate situational awareness in the event of a disaster.

Key Points: 
  • HAMBURG, BOCHUM and DARMSTADT, Germany, July 27, 2022 /PRNewswire/ - CGI (NYSE: GIB) (TSX: GIB.A) announces CGI Sense360, its cloud-based, smart analytics platform that gives emergency responders holistic and accurate situational awareness in the event of a disaster.
  • Using comprehensive data sources and augmented reality, the platform creates a visual situation overview that helps organizations more efficiently organize and accelerate rescue operations.
  • (International Search and Rescue) in Germany is a project partner in the design and development of CGI Sense360.
  • And, it is precisely this information that the new cloud-based data analytics platform CGI Sense360 can provide."

Field Trip Receives Notice of Allowance for US Patent Application Covering FT-104 (Isoprocin Glutarate), its Novel Psychedelic Molecule in Development

Retrieved on: 
Tuesday, January 11, 2022
Patient, Research, LaSalle Street Station, Psilocybin, File, COVID-19, Safety, NASDAQ, GLOBE, Toronto Stock Exchange, Instagram, USPTO, Field trip, Patent, Solubility, Phrase, PCT, ISR, Private Securities Litigation Reform Act, TSX, Twitter, Family, China International Search and Rescue Team, TIHKAL, Risk, Toxicology, Pharmaceutical industry

17/364,047 for claims related to FT-104 (informally known as Isoprocin Glutarate), Field Trips first novel psychedelic molecule in development.

Key Points: 
  • 17/364,047 for claims related to FT-104 (informally known as Isoprocin Glutarate), Field Trips first novel psychedelic molecule in development.
  • The international (PCT) patent application provides Field Trip with deferred patent filing rights in 150+ countries.
  • Field Trip expects the patent for Tryptamine Prodrugs to be issued in February 2022 and it will expire in 2040.
  • About Field Trip Health Ltd.
    Field Trip is a global leader in the development and delivery of psychedelic therapies.